Overseas regulatory announcement - form 8-K
Filed with HKEX · Stock code 9688 · · 112 pages · English
Summary by 6ix AI
The filing includes details about a securities purchase agreement and a registration rights agreement with accredited investors. The company expects to raise significant proceeds to fund development and general corporate purposes. This announcement serves to inform investors about the terms of the transaction and related agreements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Zai Lab
- Private placement of american depositary shares and issuance of underlying shares under general mandate
- Charter of the nominating and corporate governance committee
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
- Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Later from Zai Lab
- Inside information - update on first data from global Phase 1B clinical trial
- Notice of audit committee action
- Voluntary announcement - closing of the private placement of american depositary shares
- Next Day Disclosure Return
- Unaudited results for the three and nine months ended September 30, 2026 and corporate updates
Follow Zai Lab into a list and get an email when it puts out news.
Follow Zai Lab